Prothena Biosciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Prothena Biosciences sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 1 currently recruiting 3 completed early-phase tilt upper quartile by trial count

Prothena Biosciences: 8 sponsored US clinical trials, 1 recruiting.

Prothena Biosciences sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary Amyloidosis, with 1 trials.

Upper-quartile sponsor footprint

Prothena Biosciences sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 1

Phase 1 Study of PRX019 in Healthy Adult Volunteers

NCT06699680
TERMINATED Phase 3

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

NCT04973137
TERMINATED Phase 2

Study in Subjects With Light Chain (AL) Amyloidosis

NCT03154047
COMPLETED Phase 2

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

NCT02632786
TERMINATED Phase 2

Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

NCT02613182
COMPLETED

Quality of Life (QOL) Registry for Patients With AL Amyloidosis

NCT02574676
TERMINATED Phase 3

The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis

NCT02312206
COMPLETED Phase 1

Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis

NCT01707264

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 3 2

Therapeutic Areas

Primary Amyloidosis 1
Healthy Participants Study 1

What is open in the Prothena Biosciences pipeline

1 recruiting of 8 indexed (13% open); 3 completed (38%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Primary Amyloidosis (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Prothena Biosciences: open-pipeline peers nationwide

Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

Prothena Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%10%20%30%40% Total trials Recruiting share Prothena BiosciencesAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Addario Lung Cancer Medical InstituteAmerican UniversityAnnexonAnsun Biopharma
Prothena Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Prothena Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Prothena Biosciences page

8 registered trials is a research-attention snapshot, not an endorsement of Prothena Biosciences or any single study.

  • 1 of Prothena Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Primary Amyloidosis is the condition Prothena Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary Amyloidosis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Prothena Biosciences pipeline card: 8 registered trials from official public datasets.Report a data error.